Forte Biosciences, Inc. (FBRX)
NASDAQ
76.99
0.00 (0.00%)
Closed
Aug 28, 2026
Day's Range
76.9976.99
52 wk Range
10.1177.20
Financial Statements - FBRX - Forte Biosciences, Inc.
Revenue
0
Net Income
-69.37M▼ 95.5%
EBITDA
-70.59M▼ 93.1%
Free Cash Flow
-50.99M▼ 65.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -70.65M | -36.60M | -32.48M | -13.89M | -21.48M | -14.22M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -396K | -190K | -114K | -145K | -222K | -32.26M |
| Pre Tax Income | -68.33M | -35.47M | -31.47M | -13.87M | -21.70M | -46.48M |
| Income Tax | 1.03M | - | - | - | - | - |
| Net Income | -69.37M | -35.47M | -31.47M | -13.87M | -21.70M | -46.48M |
| EPS Basic | -4.71 | -12.17 | -25 | -20 | -38.75 | -158 |
| EPS Diluted | -4.71 | -12.17 | -25 | -20 | -38.75 | -158 |
| Basic Shares Outstanding | 14.71M | 2.91M | 1.26M | 695.34K | 558.71K | 294.35K |
| Diluted Shares Outstanding | 14.71M | 2.91M | 1.26M | 695.34K | 558.71K | 294.35K |
| Ebit | -70.65M | -36.60M | -32.48M | -13.89M | -21.48M | -14.22M |
| Ebitda | -70.59M | -36.56M | -32.47M | -13.89M | -21.45M | 17.88M |
| Net Income Continuous Operations | -69.37M | -35.47M | -31.47M | -13.87M | -21.70M | -46.48M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
